Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments.

We propose that there is an opportunity to devise new cancer therapies based on the recognition that tumors have properties of ecological systems. Traditionally, localized treatment has targeted the cancer cells directly by removing them (surgery) or killing them (chemotherapy and radiation). These modes of therapy have not always been effective because many tumors recur after these therapies, either because not all of the cells are killed (local recurrence) or because the cancer cells had already escaped the primary tumor environment (distant recurrence). There has been an increasing recognition that the tumor microenvironment contains host noncancer cells in addition to cancer cells, interacting in a dynamic fashion over time. The cancer cells compete and/or cooperate with nontumor cells, and the cancer cells may compete and/or cooperate with each other. It has been demonstrated that these interactions can alter the genotype and phenotype of the host cells as well as the cancer cells. The interaction of these cancer and host cells to remodel the normal host organ microenvironment may best be conceptualized as an evolving ecosystem. In classic terms, an ecosystem describes the physical and biological components of an environment in relation to each other as a unit. Here, we review some properties of tumor microenvironments and ecological systems and indicate similarities between them. We propose that describing tumors as ecological systems defines new opportunities for novel cancer therapies and use the development of prostate cancer metastases as an example. We refer to this as "ecological therapy" for cancer.

[1]  K. Pienta,et al.  The "emigration, migration, and immigration"of prostate cancer. , 2005, Clinical prostate cancer.

[2]  C. Guruvayoorappan Tumor Versus Tumor-Associated Macrophages: How Hot is the Link? , 2008, Integrative cancer therapies.

[3]  G. Clines,et al.  Molecular mechanisms and treatment of bone metastasis , 2008, Expert Reviews in Molecular Medicine.

[4]  Alissa M. Weaver,et al.  Tumor Morphology and Phenotypic Evolution Driven by Selective Pressure from the Microenvironment , 2006, Cell.

[5]  R. Weinberg,et al.  Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. , 2001, Experimental cell research.

[6]  K. Pienta,et al.  The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites , 2008, Leukemia.

[7]  A. Lipton Treatment of bone metastases and bone pain with bisphosphonates. , 2007, Supportive cancer therapy.

[8]  Monica L Guzman,et al.  Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. , 2008, Blood.

[9]  B. Samuelsson,et al.  Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. , 2008, Bone.

[10]  Kornelia Polyak,et al.  Microenvironmental regulation of cancer development. , 2008, Current opinion in genetics & development.

[11]  A. Aboussekhra,et al.  Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. , 2008, Cancer research.

[12]  R. Kast,et al.  Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure. , 2009, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[13]  L. Pelus Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand , 2008, Current opinion in hematology.

[14]  C. Hall,et al.  Ecosystem Modeling in Theory and Practice: An Introduction with Case Histories , 1990 .

[15]  A. Moustakas,et al.  Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer , 2007 .

[16]  M. Begon,et al.  Ecology: Individuals, Populations and Communities , 1986 .

[17]  S. Nadler,et al.  CTLA4 Expression Is an Indicator and Regulator of Steady-State CD4+FoxP3+ T Cell Homeostasis1 , 2008, The Journal of Immunology.

[18]  Matthew R. Smith Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. , 2008, Urologic oncology.

[19]  L. Rosanò,et al.  The endothelin axis in cancer. , 2008, The international journal of biochemistry & cell biology.

[20]  J. McGee,et al.  Macrophages in human breast disease: a quantitative immunohistochemical study. , 1988, British Journal of Cancer.

[21]  Jeremy J. W. Chen,et al.  Pathophysiology of tumor-associated macrophages. , 2008, Advances in clinical chemistry.

[22]  G. Hahn,et al.  Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. L. Kitching Systems Ecology: An Introduction to Ecological Modelling , 1983 .

[24]  G. Tucker Integrins: Molecular targets in cancer therapy , 2006, Current oncology reports.

[25]  Yi Lu,et al.  Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. , 2006, Cancer research.

[26]  A. Aranda-Anzaldo Cancer Development and Progression: A Non-Adaptive Process Driven by Genetic Drift , 2001, Acta biotheoretica.

[27]  Brian Bierie,et al.  A delicate balance: TGF-beta and the tumor microenvironment. , 2007, Journal of cellular biochemistry.

[28]  N. Nishimoto,et al.  The blockade of IL-6 signaling in rational drug design. , 2008, Current pharmaceutical design.

[29]  E. Small,et al.  Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. , 2006, Urologic oncology.

[30]  S. Chiou,et al.  cAMP/PKA Regulates Osteogenesis, Adipogenesis and Ratio of RANKL/OPG mRNA Expression in Mesenchymal Stem Cells by Suppressing Leptin , 2008, PloS one.

[31]  E. Odum Fundamentals of Ecology. , 1955 .

[32]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[33]  D. S. Coffey,et al.  Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect". , 2006, JAMA.

[34]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[35]  K. Pienta,et al.  Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer , 2008, Journal of cellular biochemistry.

[36]  H. Kampinga,et al.  Nuclear matrix as a target for hyperthermic killing of cancer cells. , 1998, Cell stress & chaperones.

[37]  P. Allavena,et al.  Cancer related inflammation: the macrophage connection. , 2008, Cancer letters.

[38]  J. Wallace,et al.  Suppressive effects of nitric oxide‐releasing prednisolone NCX‐1015 on the allergic pleural eosinophil recruitment in rats , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[39]  A. Testori,et al.  Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. , 2008, Recent patents on anti-cancer drug discovery.

[40]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[41]  A. J. Willis The ecosystem : an evolving concept viewed historically , 1997 .

[42]  J. Klein-Nulend,et al.  Stem cells from adipose tissue allow challenging new concepts for regenerative medicine. , 2007, Tissue engineering.

[43]  J. Gallagher Advances in bone biology and new treatments for bone loss. , 2008, Maturitas.

[44]  W. Hamilton,et al.  The Evolution of Cooperation , 1984 .

[45]  M. Kassem,et al.  Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells. , 2008, Bone.

[46]  H. Allgayer,et al.  An introduction to molecular targeted therapy of cancer. , 2008, Advances in medical sciences.

[47]  J. Masters,et al.  Interferon-γ Reduces Cell Surface Expression of Annexin 2 and Suppresses the Invasive Capacity of Prostate Cancer Cells* , 2008, Journal of Biological Chemistry.

[48]  M. Washington,et al.  TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.

[49]  K. Flaherty Sorafenib: delivering a targeted drug to the right targets , 2007, Expert review of anticancer therapy.

[50]  Brian Bierie,et al.  Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. , 2008, Cancer research.

[51]  M. Teixeira,et al.  The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature. , 2008, Arthritis and rheumatism.

[52]  John D Nagy,et al.  The ecology and evolutionary biology of cancer: a review of mathematical models of necrosis and tumor cell diversity. , 2005, Mathematical biosciences and engineering : MBE.

[53]  D. McNeel,et al.  Endothelin Receptor Antagonists in Cancer Therapy , 2007, Cancer investigation.

[54]  Lisa M. Coussens,et al.  Immune cells as mediators of solid tumor metastasis , 2008, Cancer and Metastasis Reviews.

[55]  Kyle Summers,et al.  Positive selection in the evolution of cancer , 2006, Biological reviews of the Cambridge Philosophical Society.

[56]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[57]  T. Tlsty,et al.  Stromal cells can contribute oncogenic signals. , 2001, Seminars in cancer biology.

[58]  Brian Bierie,et al.  A delicate balance: TGF‐β and the tumor microenvironment , 2007, Journal of cellular biochemistry.

[59]  Mel Greaves,et al.  Cancer causation: the Darwinian downside of past success? , 2002, The Lancet. Oncology.

[60]  Brian Bierie,et al.  Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.

[61]  B. O'connor,et al.  Heparin and structurally related polymers attenuate eotaxin‐1 (CCL11) release from human airway smooth muscle , 2008, British journal of pharmacology.

[62]  Matthew J. Craig,et al.  Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. , 2007, Cancer research.

[63]  W. Sierralta,et al.  Marrow-derived mesenchymal stem cells: Role in epithelial tumor cell determination , 2004, Clinical & Experimental Metastasis.

[64]  G. Jayson,et al.  A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis , 2006, Expert opinion on therapeutic targets.

[65]  P. Hein,et al.  Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.

[66]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[67]  Robert J. Gillies,et al.  A microenvironmental model of carcinogenesis , 2008, Nature Reviews Cancer.

[68]  L. Coussens,et al.  Polarized immune responses differentially regulate cancer development , 2008, Immunological reviews.

[69]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[70]  J. Elser,et al.  Biological Stoichiometry in Human Cancer , 2007, PloS one.

[71]  Thomas S. Deisboeck,et al.  Modeling Tumors as Complex Biosystems: An Agent-Based Approach , 2006 .

[72]  John Cairns,et al.  Mutation selection and the natural history of cancer , 1975, Nature.

[73]  K. Pienta,et al.  Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  V. Quaranta,et al.  Integrative mathematical oncology , 2008, Nature Reviews Cancer.

[75]  Z. Shao,et al.  The human myoepithelial cell is a natural tumor suppressor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  K. Pienta,et al.  Evolution of cooperation among tumor cells , 2006, Proceedings of the National Academy of Sciences.

[77]  Zeljko Vujaskovic,et al.  Re-setting the biologic rationale for thermal therapy , 2005, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[78]  T. Ratliff TGF-Beta Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004 .

[79]  K. Pienta,et al.  Cancer as a complex adaptive system. , 1996, Medical hypotheses.

[80]  Bert Vogelstein,et al.  Genetic instability and darwinian selection in tumours , 1999 .

[81]  P. Vineis Cancer as an evolutionary process at the cell level: an epidemiological perspective. , 2003, Carcinogenesis.

[82]  M. Begon,et al.  Ecology: Individuals, Populations and Communities , 1986 .

[83]  Noam Brown,et al.  Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors , 2001, Journal of leukocyte biology.

[84]  H C Charles,et al.  Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. , 1996, Cancer research.

[85]  F. Lee,et al.  Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor , 2008, Cancer Chemotherapy and Pharmacology.

[86]  Stephen E. Jones Metastatic breast cancer: the treatment challenge. , 2008, Clinical breast cancer.

[87]  A. Veves,et al.  DPP4 Inhibitors: a new approach in diabetes treatment , 2008, Advances in therapy.

[88]  A. Moustakas,et al.  Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. , 2007, Biochimica et biophysica acta.

[89]  J. Shaw,et al.  Primary breast myoepithelial cells exert an invasion‐suppressor effect on breast cancer cells via paracrine down‐regulation of MMP expression in fibroblasts and tumour cells , 2003, The Journal of pathology.

[90]  H. Moses,et al.  Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. , 2007, The Journal of clinical investigation.

[91]  G. Roodman,et al.  Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. , 2007, Cancer research.

[92]  A. Zwinderman,et al.  A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue , 2008, Annals of the rheumatic diseases.

[93]  G. Mundy Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[94]  T. Guise,et al.  The vicious cycle of bone metastases. , 2002, Journal of musculoskeletal & neuronal interactions.

[95]  Mel Greaves,et al.  Darwinian medicine: a case for cancer , 2007, Nature Reviews Cancer.

[96]  J. Klein-Nulend,et al.  Prostaglandins differentially affect osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells. , 2007, Tissue engineering.

[97]  J. van der Zee,et al.  First results of triple‐modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma , 2005, Cancer.